Are we any closer to combating Ebola infections?

The Lancet

Volumn 375, Issue 9729, 2010, Pages 1850-1852

  Feldmann, Heinz ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; NEW DRUG; PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE; RNA POLYMERASE; SMALL INTERFERING RNA; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VESICULAR STOMTITIS VIRUS VECTOR; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BRAIN EDEMA; CENTRAL AFRICA; DRUG APPROVAL; EBOLA HEMORRHAGIC FEVER; FATALITY; FILOVIRIDAE; FILOVIRUS INFECTION; FUNDING; GENE SILENCING; GERMANY; HUMAN; KIDNEY FAILURE; MARBURG VIRUS; NEEDLESTICK INJURY; NONHUMAN; NURSING CARE; PATIENT CARE; PRIORITY JOURNAL; RNA INTERFERENCE; RUSSIAN FEDERATION; SHOCK; UNITED KINGDOM; UNITED STATES; VACCINATION; VIRUS GENE;

EID: 77952708376     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60597-1     Document Type: Note

References (14)

1. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ 338 (2009) b1223
2. Sanchez A., Geisbert T.W., and Feldmann H. Marburg and Ebola viruses. In: Knipe D.M., Howley P.M., et al. (Eds). Fields virology (2007), Wolters Kluwer/Lippincott Williams and Wilkins, Philadelphia 1409-1448
3. Groseth A., Feldmann H., and Strong J.E. The ecology of Ebola virus. Trends Microbiol 15 (2007) 408-416
4. Geisbert T.W., Lee A., Robbins M., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375 (2010) 1896-1905
5. Geisbert T.W., Hensley L.E., Kagan E., et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 193 (2006) 1650-1657
6. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., and Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8 (2002) 503-507
7. Bente D., Gren J., Strong J.E., and Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2 (2009) 12-17
8. Enterlein S., Warfield K.L., Swenson D.L., et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 50 (2006) 984-993
9. Warfield K.L., Swenson D.L., Olinger G.G., et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2 (2006) e1
10. Bray M., and Paragas J. Experimental therapy of filovirus infections. Antiviral Res 54 (2002) 1-17
11. Feldmann H., Jones S.M., Schnittler H.J., and Geisbert T. Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 6 (2005) 823-830
12. Geisbert T.W., Hensley L.E., Jahrling P.B., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362 (2003) 1953-1958
13. Hensley L.E., Stevens E.L., Yan S.B., et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 196 suppl 2 (2007) S390-S399
14. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., et al. Effective post exposure treatment of Ebola infection. PLoS Pathog 3 (2007) e2